CA2790802C - Oligoribonucleotides immunostimulateurs - Google Patents

Oligoribonucleotides immunostimulateurs Download PDF

Info

Publication number
CA2790802C
CA2790802C CA2790802A CA2790802A CA2790802C CA 2790802 C CA2790802 C CA 2790802C CA 2790802 A CA2790802 A CA 2790802A CA 2790802 A CA2790802 A CA 2790802A CA 2790802 C CA2790802 C CA 2790802C
Authority
CA
Canada
Prior art keywords
orn
seq
immunostimulatory
rna
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2790802A
Other languages
English (en)
Other versions
CA2790802A1 (fr
Inventor
Alexandra Forsbach
Joerg Vollmer
Grayson B. Lipford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Belgium SA
Original Assignee
Zoetis Belgium SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Belgium SA filed Critical Zoetis Belgium SA
Priority claimed from CA2630738A external-priority patent/CA2630738C/fr
Publication of CA2790802A1 publication Critical patent/CA2790802A1/fr
Application granted granted Critical
Publication of CA2790802C publication Critical patent/CA2790802C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Linvention concerne des compositions immunostimulatrices et lutilisation de ces composés dans la préparation de médicaments utilisés dans le traitement de maladies ainsi que dans des utilisations in vitro. Les compositions de linvention comprennent, en particulier, des oligoribonucléotides immunostimulateurs incorporant un motif séquentiel immunostimulateur dépendant de la séquence. Des modifications spécifiques associées à des liaisons phosphate, des analogues des nucléotides, des composés daddition et des combinaisons de ceux-ci sont décrites. Les compositions de linvention, pouvant éventuellement contenir un antigène, peuvent être utilisées seules ou conjointement à dautres traitements pour stimuler ou améliorer une réponse immune. Linvention concerne également des compositions et des méthodes utilisées dans le traitement dun sujet souffrant dune infection, dun cancer, dune allergie, dasthme, dun remodelage des voies aériennes ou dune immunodéficience. Les oligoribonucléotides immunostimulateurs de linvention stimuleraient le récepteur 8 de type Toll (TLR8). Spécifiquement, linvention a trait à un oligoribonucléotide comprenant la séquence telle quétablie dans le numéro ID SEQ 21.
CA2790802A 2005-11-25 2006-11-22 Oligoribonucleotides immunostimulateurs Active CA2790802C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73952905P 2005-11-25 2005-11-25
US60/739,529 2005-11-25
US77898906P 2006-03-03 2006-03-03
US60/778,989 2006-03-03
CA2630738A CA2630738C (fr) 2005-11-25 2006-11-22 Oligoribonucleotides immunostimulateurs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2630738A Division CA2630738C (fr) 2005-11-25 2006-11-22 Oligoribonucleotides immunostimulateurs

Publications (2)

Publication Number Publication Date
CA2790802A1 CA2790802A1 (fr) 2007-05-31
CA2790802C true CA2790802C (fr) 2016-07-12

Family

ID=40206401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2790802A Active CA2790802C (fr) 2005-11-25 2006-11-22 Oligoribonucleotides immunostimulateurs

Country Status (3)

Country Link
CN (1) CN101331229B (fr)
CA (1) CA2790802C (fr)
ZA (1) ZA200804303B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021064614A1 (fr) * 2019-09-30 2021-04-08 Janssen Biopharma, Inc. Agonistes du récepteur de type toll 7 et/ou toll 8 et utilisations associées
CN115137736A (zh) * 2022-02-17 2022-10-04 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种抗非洲猪瘟病毒的药物及其筛选方法

Also Published As

Publication number Publication date
CA2790802A1 (fr) 2007-05-31
CN101331229B (zh) 2012-08-29
ZA200804303B (en) 2009-03-25
CN101331229A (zh) 2008-12-24

Similar Documents

Publication Publication Date Title
CA2630738C (fr) Oligoribonucleotides immunostimulateurs
US20100144846A1 (en) Oligoribonucleotides and uses thereof
US20060241076A1 (en) Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US8466124B2 (en) RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
CA2790802C (fr) Oligoribonucleotides immunostimulateurs
MX2008006770A (en) Immunostimulatory oligoribonucleotides

Legal Events

Date Code Title Description
EEER Examination request